Safety profile: No systemic toxicity was reported, and adverse effects were restricted to moderate transitory erythema in less than 5% of individuals
The three-way comparison between these incretin compounds helps researchers understand where each sits on the efficacy-safety spectrum
This PDC is in phase I/II clinical trials for the treatment of patients with metastatic non-small cell lung cancer
So far great product
The 2026 update: Ro now sells Foundayo (orforglipron, the once-daily pill with no food restrictions, FDA-approved April 2026)
J Med Chem 58:888896 Liu N, Zhang Y, Lei Y, Wang R, Zhan M, Liu J, An Y, Zhou Y, Zhan J et al (2022) Design and evaluation of a novel peptidedrug conjugate covalently targeting SARS-CoV-2 papain-like protease